All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy


Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
You're logged in! Click here any time to manage your account or log out.
You're logged in! Click here any time to manage your account or log out.

EHA2023 abstracts: What’s hot in AML?

Jun 7, 2023

Bookmark this article

To help navigate the exciting content being presented at the European Hematology Association (EHA) 2023 Congress, the AML Hub Steering Committee have provided their recommendations of the top abstracts to look for.​

Friday, June 9






Oral presentation

Preliminary results of QUIWI: a double blinded, randomized clinical trial comparing standard chemotherapy plus quizartinib versus placebo in adult patients with newly diagnosed FLT3-ITD wild-type AML

Pau Montesinos


Oral presentation

Updated results of VEN-A-QUI study: a phase 1-2 trial to assess the safety and efficacy of triplets for newly diagnosed unfit AML patients: azacitidine or low-dose cytarabine with venetoclax and quizartinib

Juan Miguel Bergua Burgues


Oral presentation

An entirely oral regimen of oral-ATO, ATRA and ascorbic acid in risk-adapted treatment of newly-diagnosed APL resulted in excellent clinical/molecular responses with durable remission

Harry Gill


Oral presentation

FLAG-IDA combined with gemtuzumab ozogamicin (GO) reduced MRD levels and improved overall survival in NPM1mut AML independent of FLT3 and MRD status, results from the AML19 trial

Nigel Russell


Poster presentation

Day 14 measurable residual disease assessment predicts treatment outcomes in patients with acute myeloid leukemia treated with intensive chemotherapy - results of the PALG-AML1/2016 study

Agnieszka Wierzbowska


Poster presentation

A first-in-human study of CD123 NK cell engager SAR443579 in relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia or high risk-myelodysplasia

Anthony Selwyn Stein


Poster presentation

Clinical outcomes of NPM1-mutated acute myeloid leukemia (AML) patients with measurable residual disease (MRD) relapse after achievement of a first MRD-negative remission

Madlen Jentzsch


Poster presentation

Long-term outcomes of stem cell transplant in older patients with acute myeloid leukemia treated with venetoclax + HM therapies

Keith Pratz


Poster presentation

Results of a randomized placebo-controlled phase 2 study of hypomethylating agents with or without eltrombopag in elderly AML patients (DELTA)

Katja Sockel


Poster presentation

Olutasidenib in post-venetoclax patients with mutant IDH1 AML

Jorge Cortes


Poster presentation

Phase 1b omniverse trial: safety and tolerability of oral azacitidine in combination with venetoclax for treatment of acute myeloid leukemia

Shaun Fleming

Saturday, June 20

Sunday, June 11

EHA 2023 abstracts

To download this document, click below.

Download here

More about...


Subscribe to get the best content related to AML delivered to your inbox